Disease entity representation in study cohort
| Disease entity . | B/T cell . | Total n . | % . | HMW . | FFPE . | LLD (<20%)* . |
|---|---|---|---|---|---|---|
| MCL | B | 39 | 13.9 | 23 | 15 | 1 |
| CLL | B | 37 | 13.2 | 37 | 0 | 0 |
| FL | B | 36 | 12.9 | 18 | 18 | 3 |
| PCM | B | 24 | 8.6 | 24 | 0 | 0 |
| DLBCL | B | 20 | 7.1 | 4 | 17 | 0 |
| B-ALL† | B | 20 | 7.1 | 20 | 0 | 0 |
| BL | B | 18 | 6.4 | 8 | 10 | 0 |
| MZL | B | 6 | 2.1 | 6 | 0 | 1 |
| MALT | B | 3 | 1.1 | 0 | 3 | 0 |
| SMZL | B | 1 | 0.4 | 1 | 0 | 0 |
| T-ALL | T | 42 | 15.0 | 42 | 0 | 0 |
| ALCL | T | 13 | 4.6 | 2 | 11 | 0 |
| AITL | T | 9 | 3.2 | 3 | 6 | 1 |
| MF | T | 3 | 1.1 | 1 | 2 | 1 |
| SS | T | 3 | 1.1 | 3 | 0 | 0 |
| EATL | T | 2 | 0.7 | 0 | 2 | 0 |
| C-ALCL | T | 1 | 0.4 | 0 | 1 | 0 |
| T-LBL | T | 1 | 0.4 | 0 | 1 | 0 |
| PTCL-NOS | T | 1 | 0.4 | 0 | 1 | 0 |
| Intestinal T-cell lymphoma, not otherwise specified | T | 1 | 0.4 | 0 | 1 | 0 |
| Total | 280 | 100.0 | 192 | 88 | 7 |
| Disease entity . | B/T cell . | Total n . | % . | HMW . | FFPE . | LLD (<20%)* . |
|---|---|---|---|---|---|---|
| MCL | B | 39 | 13.9 | 23 | 15 | 1 |
| CLL | B | 37 | 13.2 | 37 | 0 | 0 |
| FL | B | 36 | 12.9 | 18 | 18 | 3 |
| PCM | B | 24 | 8.6 | 24 | 0 | 0 |
| DLBCL | B | 20 | 7.1 | 4 | 17 | 0 |
| B-ALL† | B | 20 | 7.1 | 20 | 0 | 0 |
| BL | B | 18 | 6.4 | 8 | 10 | 0 |
| MZL | B | 6 | 2.1 | 6 | 0 | 1 |
| MALT | B | 3 | 1.1 | 0 | 3 | 0 |
| SMZL | B | 1 | 0.4 | 1 | 0 | 0 |
| T-ALL | T | 42 | 15.0 | 42 | 0 | 0 |
| ALCL | T | 13 | 4.6 | 2 | 11 | 0 |
| AITL | T | 9 | 3.2 | 3 | 6 | 1 |
| MF | T | 3 | 1.1 | 1 | 2 | 1 |
| SS | T | 3 | 1.1 | 3 | 0 | 0 |
| EATL | T | 2 | 0.7 | 0 | 2 | 0 |
| C-ALCL | T | 1 | 0.4 | 0 | 1 | 0 |
| T-LBL | T | 1 | 0.4 | 0 | 1 | 0 |
| PTCL-NOS | T | 1 | 0.4 | 0 | 1 | 0 |
| Intestinal T-cell lymphoma, not otherwise specified | T | 1 | 0.4 | 0 | 1 | 0 |
| Total | 280 | 100.0 | 192 | 88 | 7 |
AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large-cell lymphoma; B-ALL, B-cell acute lymphoblastic leukemia; BL, Burkitt lymphoma; C-ALCL, CD30+ anaplastic large cell lymphoma; DLBCL, diffuse large B-cell lymphoma; EATL, enteropathy-associated T-cell lymphoma; FL, follicular lymphoma; LLD, low-level disease; MALT, mucosa-associated lymphoid tissue; MF, mycosis fungoides; MZL, marginal zone lymphoma; PCM, plasma cell myeloma; PTCL-NOS, peripheral T-cell lymphoma, not otherwise specified; SMZL, splenic marginal zone lymphoma; SS, Sézary syndrome; T-ALL, T-cell acute lymphoblastic leukemia; T-LBL, T-lymphoblastic lymphoma.
Classified as <20% tumor infiltration.
Sixteen B-ALL samples were B-cell precursor ALL.